title: Therapeutic vaccines for non-Hodgkin B-cell lymphoma.
abstract: Despite current therapeutic strategies for B-cell lymphoma, including chemotherapy and transplantation, the majority of patients are not cured. The characterisation of several tumour antigens has made immunotherapy an interesting approach to the treatment of patients with lymphoma. The idiotype region in the immunoglobulin expressed by the tumour B cells is not only a clonal marker but also a tumour-specific antigen. For this reason, the idiotype is an ideal target for immunotherapy. Extensive studies of idiotype vaccination have been done in murine lymphoma models and some of these strategies are now being tested in clinical trials. In the last few years, new strategies to improve the immune response against lymphoma cells have been studied, including the use of DNA or recombinant viruses encoding tumour-antigens, genetically modified tumour cells and a number of immune adjuvants targeting dendritic cells, T cells or NK cells.
authors.affiliation: Department of Clinical Hematology, Hospital Santa Creu i Sant Pau, Barcelona, Spain. Jbriones@santpau.cat
authors.forename: Javier
authors.initials: J
authors.lastname: Briones
mesh_terms: D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy; D016393:Lymphoma, B-Cell / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines
references.citation: Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8200-4
references.pmid: 7545296
references.citation: Nat Med. 1997 May;3(5):558-61
references.pmid: 9142127
references.citation: Curr Opin Oncol. 1998 Nov;10(6):533-41
references.pmid: 9818232
references.citation: Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):703-8
references.pmid: 9892697
references.citation: Cancer Immunol Immunother. 2008 Aug;57(8):1115-24
references.pmid: 18193223
references.citation: Annu Rev Med. 1999;50:507-29
references.pmid: 10073291
references.citation: Blood. 2006 Mar 1;107(5):1955-62
references.pmid: 16210338
references.citation: Nat Immunol. 2002 Jul;3(7):611-8
references.pmid: 12087419
references.citation: Nat Med. 1998 Nov;4(11):1281-6
references.pmid: 9809552
references.citation: Nature. 1993 Apr 22;362(6422):755-8
references.pmid: 8469286
references.citation: Blood. 2007 Nov 1;110(9):3192-201
references.pmid: 17616639
references.citation: Blood. 2002 Apr 1;99(7):2512-7
references.pmid: 11895787
references.citation: Adv Drug Deliv Rev. 2006 Oct 1;58(8):931-47
references.pmid: 17030074
references.citation: Blood. 2002 Mar 1;99(5):1517-26
references.pmid: 11861263
references.citation: Nature. 1998 Mar 19;392(6673):245-52
references.pmid: 9521319
references.citation: Trends Immunol. 2001 Feb;22(2):102-7
references.pmid: 11286712
references.citation: Nat Med. 1996 Sep;2(9):1038-41
references.pmid: 8782465
references.citation: Immunol Today. 1994 Feb;15(2):48-51
references.pmid: 8155261
references.citation: J Immunol. 1996 Jan 1;156(1):224-31
references.pmid: 8598466
references.citation: Cancer Res. 2001 Jun 1;61(11):4497-505
references.pmid: 11389081
references.citation: J Leukoc Biol. 2000 Jan;67(1):2-17
references.pmid: 10647992
references.citation: Blood. 1997 May 1;89(9):3129-35
references.pmid: 9129015
references.citation: Cancer Res. 2006 Apr 15;66(8):4496-502
references.pmid: 16618777
references.citation: Annu Rev Med. 2004;55:355-72
references.pmid: 14746526
references.citation: J Exp Med. 2007 Oct 29;204(11):2641-53
references.pmid: 17923500
references.citation: Annu Rev Immunol. 2007;25:297-336
references.pmid: 17150027
references.citation: N Engl J Med. 2004 Nov 18;351(21):2159-69
references.pmid: 15548776
references.citation: Trends Mol Med. 2001 Dec;7(12):566-72
references.pmid: 11733220
references.citation: Proc Natl Acad Sci U S A. 1978 May;75(5):2411-5
references.pmid: 97669
references.citation: Annu Rev Med. 2004;55:477-503
references.pmid: 14746532
references.citation: Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10067-71
references.pmid: 9707601
references.citation: Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14660-5
references.pmid: 9405669
references.citation: Nat Rev Cancer. 2008 Feb;8(2):108-20
references.pmid: 18219306
references.citation: Nat Rev Immunol. 2007 May;7(5):329-39
references.pmid: 17438573
references.citation: Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6916-23
references.pmid: 16203783
references.citation: Cancer Res. 2002 Jun 1;62(11):3195-9
references.pmid: 12036933
references.citation: Bull Cancer. 2008 Mar;95(3):320-6
references.pmid: 18390412
references.citation: J Exp Med. 2000 May 15;191(10):1699-708
references.pmid: 10811863
references.citation: J Immunol. 2002 Nov 1;169(9):5227-35
references.pmid: 12391241
references.citation: Blood. 2008 Aug 1;112(3):610-8
references.pmid: 18519811
references.citation: Blood. 1998 Aug 15;92(4):1184-90
references.pmid: 9694706
references.citation: Nat Med. 2005 Sep;11(9):986-91
references.pmid: 16116429
references.citation: Nat Med. 1999 Oct;5(10):1171-7
references.pmid: 10502821
references.citation: J Clin Oncol. 2000 Dec 1;18(23):3964-73
references.pmid: 11099326
references.citation: Cancer Res. 2002 Oct 15;62(20):5845-52
references.pmid: 12384547
references.citation: J Clin Invest. 1998 Mar 1;101(5):1133-41
references.pmid: 9486984
references.citation: J Immunol. 2000 May 1;164(9):4797-803
references.pmid: 10779787
references.citation: Blood. 2001 Mar 1;97(5):1370-7
references.pmid: 11222382
references.citation: Nat Rev Immunol. 2007 Aug;7(8):585-98
references.pmid: 17653126
references.citation: N Engl J Med. 1992 Oct 22;327(17):1209-15
references.pmid: 1406793
references.citation: J Clin Invest. 2000 Apr;105(8):1031-4
references.pmid: 10772644
references.citation: Immunol Rev. 2004 Jun;199:201-16
references.pmid: 15233736
references.citation: J Immunol. 1996 May 15;156(10):3858-65
references.pmid: 8621924
references.citation: J Exp Med. 1997 Oct 20;186(8):1247-56
references.pmid: 9334364
references.citation: Nat Immunol. 2001 Mar;2(3):203-9
references.pmid: 11224518
references.citation: J Natl Cancer Inst. 2003 Apr 2;95(7):548-55
references.pmid: 12671023
references.citation: Nat Biotechnol. 1999 Mar;17(3):253-8
references.pmid: 10096292
references.citation: J Immunol. 1999 Apr 15;162(8):4790-5
references.pmid: 10202021
references.citation: J Immunol. 1997 Apr 1;158(7):3270-6
references.pmid: 9120283
references.citation: Nat Med. 1996 Jan;2(1):52-8
references.pmid: 8564842
references.citation: J Virol. 1996 Jul;70(7):4805-10
references.pmid: 8676512
references.citation: Nature. 2000 Dec 7;408(6813):659-60
references.pmid: 11130055
references.citation: Blood. 2000 Nov 1;96(9):2917-24
references.pmid: 11049967